Arcturus Therapeutics (ARCT) Misses Q2 EPS by 130c, misses on revenue

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($1.98), $1.30 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $28.38 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Robinhood prices $2B convertible notes offering due 2029